Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Total Debt: 2010-2025

Historic Total Debt for UNITED THERAPEUTICS (UTHR) over the last 11 years, with Mar 2025 value amounting to $200.0 million.

  • UNITED THERAPEUTICS's Total Debt fell 66.67% to $200.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $1.4 billion, marking a year-over-year decrease of 51.72%. This contributed to the annual value of $300.0 million for FY2024, which is 57.14% down from last year.
  • Per UNITED THERAPEUTICS's latest filing, its Total Debt stood at $200.0 million for Q1 2025, which was down 33.33% from $300.0 million recorded in Q4 2024.
  • UNITED THERAPEUTICS's Total Debt's 5-year high stood at $800.0 million during Q1 2021, with a 5-year trough of $200.0 million in Q1 2025.
  • Over the past 3 years, UNITED THERAPEUTICS's median Total Debt value was $600.0 million (recorded in 2024), while the average stood at $566.7 million.
  • Data for UNITED THERAPEUTICS's Total Debt shows a maximum YoY slumped of 66.67% (in 2025) over the last 5 years.
  • Over the past 5 years, UNITED THERAPEUTICS's Total Debt (Quarterly) stood at $800.0 million in 2021, then remained steady at $800.0 million in 2022, then dropped by 12.50% to $700.0 million in 2023, then crashed by 57.14% to $300.0 million in 2024, then crashed by 66.67% to $200.0 million in 2025.
  • Its Total Debt was $200.0 million in Q1 2025, compared to $300.0 million in Q4 2024 and $400.0 million in Q3 2024.